Erythropoietin stimulating agents (ESAs), which represent the first choice of treatment for patients with lower-risk MDS in general [8], and when early administered, might delay the onset of transfusion dependency [9], in this patient group are less effective even when serum erythropoietin levels are not elevated. Here, EPO is linked to myelodysplastic syndrome.